Cargando…
P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430102/ http://dx.doi.org/10.1097/01.HS9.0000846920.28798.b0 |
| _version_ | 1784779657952886784 |
|---|---|
| author | Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. |
| author_facet | Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. |
| author_sort | Reiter, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430102 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94301022022-08-31 P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430102/ http://dx.doi.org/10.1097/01.HS9.0000846920.28798.b0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Reiter, A. Gotlib, J. Álvarez-Twose, I. Radia, D. H. Luebke, J. Bobbili, P. J. Wang, A. Norregaard, C. Dimitrijević, S. Sullivan, E. Louie-Gao, M. Schwaab, J. Galinsky, I. A. Perkins, C. Sperr, W. R. Sriskandarajah, P. Chin, A. Sendhil, S. R. Duh, M. S. Valent, P. DeAngelo, D. J. P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title | P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_full | P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_fullStr | P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_full_unstemmed | P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_short | P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY |
| title_sort | p1013: overall survival in patients with systemic mastocytosis with associated hematologic neoplasm treated with avapritinib versus best available therapy |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430102/ http://dx.doi.org/10.1097/01.HS9.0000846920.28798.b0 |
| work_keys_str_mv | AT reitera p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT gotlibj p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT alvareztwosei p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT radiadh p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT luebkej p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT bobbilipj p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT wanga p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT norregaardc p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT dimitrijevics p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT sullivane p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT louiegaom p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT schwaabj p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT galinskyia p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT perkinsc p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT sperrwr p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT sriskandarajahp p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT china p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT sendhilsr p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT duhms p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT valentp p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy AT deangelodj p1013overallsurvivalinpatientswithsystemicmastocytosiswithassociatedhematologicneoplasmtreatedwithavapritinibversusbestavailabletherapy |